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Abstract
Objective: To evaluate the feasibility of implementing an integrated multicompo-
nent survivorship care model for men affected by prostate cancer.
Methods: Using a single arm prospective cohort study design, men with prostate
cancer were recruited from two regional public hospitals in Australia for a 6‐months
program that provided information and decision support, exercise and nutrition
management, specialised clinical support, and practical support through localised
and central care coordination. Carers of the men were also invited to the program.
Data were collected from multiple sources to evaluate: (1) recruitment capability
and participant characteristics; (2) appropriateness and feasibility of delivering the
specific intervention components using an electronic care management tool; and (3)
suitability of data collection procedures and proposed outcome measures.
Results: Of the 105 eligible men, 51 (consent rate 49%) participated in the program.
Of the 31 carers nominated by the men, 13 consented (consent rate 42%). All carers
and 50 (98%) men completed the program. Most (92%) men were newly diagnosed
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with localised prostate cancer. All men attended initial screening and assessment for
supportive care needs; a total of 838 episodes of contact/consultation were made by
the intervention team either in person (9%) or remotely (91%). The intervention was
implemented as proposed with no adverse events. The proposed outcome measures
and evaluation procedures were found to be appropriate.
Conclusions: Our results support the feasibility of implementing this integrated
multicomponent care model for men affected by prostate cancer.
K E YWORD S
cancer, feasibility, model of care, oncology, psycho‐oncology, prostate, quality of life,
survivorship, urology
1 | INTRODUCTION
Approximately 20,000 men are diagnosed with prostate cancer each
year in Australia and 95% of them live at least 5 years after diagnosis.1
The prostate cancer survivorship starts at the time of initial diagnosis
and treatment and remains the rest of life,2 in which men face various
challenges associated with complex treatment decisions, treatment‐
related side effects, psychological distress and the prospect of recur-
rence or progression of disease. Urinary incontinence and erectile
dysfunction are the most common treatment‐related side effects
following radical prostatectomy that negatively impact quality of life.
Other common treatment‐related side effects include bowel urgency
from radiation therapy, and deterioration in body composition, phys-
ical function, cardiometabolic toxicity and loss of libido and physical
feminisation from androgen deprivation therapy.3–6 Additionally, men
can experience acceleration of comorbid conditions associated with
their cancer treatment, such as osteopenia and osteoporosis, cardio-
vascular disease, diabetes and obesity.6 The complexity of these dis-
ease‐ and treatment‐related effects mean that many men with
prostate cancer are at risk of or experience unmet supportive care
needs. Carers of these men report unmet needs in relation to infor-
mation and health care services,7 with some studies reporting that
carers can experience greater distress than the men.8,9
Topromote comprehensive follow‐up care and improvequality life
of men with prostate cancer, the American Cancer Society (ACS) and
American Society of Clinical Oncology (ASCO) Prostate Cancer Sur-
vivorship Care Guidelines10,11 identify five key domains for action:
health promotion, surveillance, physical side effects, psychosocial
management, and care coordination. A number of studies have con-
ducted interventions to address these key areas of care. Exercise and
psychosocial interventions have been shown to improve men’s health
promotion and psychosocial outcomes and reduce physical side ef-
fects.12–14 Supported self‐management interventions have been
shown to be comparable to traditional follow‐up care15 and enhance
sexual and urinary function.16 Nutrition interventions,17 with or
without aerobic exercise, are efficacious in reducing body mass in
overweight and obese men with prostate cancer. Studies of family/
couple‐based interventions also report benefits for carers, such as
improved information and psychosocial support, better coping and
adjustment to the disease.14,18
While evidence for prostate cancer survivorship care in-
terventions has grown over the last decade, most studies to date
have focused on one area of care, with single intervention ap-
proaches that report only on the short‐term effects. These studies
often fail to recognise that many men and their carers have multiple
supportive care needs that can exist over extended periods of time.2
It is noteworthy to mention that the design and implementation for
long‐term comprehensive survivorship interventions are sometimes
restrained due to issues such as short funding periods and privately
insured health care systems.
Recent literature highlights the need to develop comprehensive
models of survivorship care that recognise themultiple co‐existing and
changing requirements that men with prostate cancer experience, and
the many service providers that need to be engaged to prevent and
manage these needs over time.2 In Australia, the recent Prostate
Cancer Survivorship Essentials Framework19 supports well‐
coordinated and responsive survivorship care, in which an inte-
grated, needs‐based approach to survivorship care is required. This
includes a tailored approach to address the complexity of each in-
dividual’s requirements through multi‐faceted health care, including
psychological, exercise and nutrition support.20 While the principles
inherent in thesemodels have becomewidely accepted, there is limited
literature that reports on the development, implementation and eval-
uation of integrated multi‐component survivorship interventions.
This paper reports the outcomes of a study that assessed the
feasibility of an integratedmulti‐component survivorship intervention
(known as TrueNTH, funded by Movember) designed for men with
prostate cancer and their partners/carers. Specifically, the aims of this
study were to evaluate: (1) recruitment capability and resulting
participant characteristics; (2) appropriateness and feasibility of
delivering the specific intervention components and using an elec-
tronic care management tool to support delivery of the intervention;
and (3) suitability of data collection procedures and proposed outcome
measures to obtain valid, reliable and complete data over time.
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2 | METHODS
2.1 | Study design
This was a single arm prospective cohort study. The study was
registered with the Australian New Zealand Clinical Trials Registry
(ACTRN12615000499583) and received ethical approvals from the
lead universities (QUT Approval Number 1400000860) and partici-
pating health services.
2.2 | Setting and sample
Based on the capacity and readiness to implement the intervention,
two regional public health services from Queensland and New South
Wales were selected to participate. Men were eligible if they: (1) were
diagnosed with localised prostate cancer within the last 3 months or
diagnosed with advanced prostate cancer at least 12 months prior to
the recruitment period; (2) were able and willing to participate in the
intervention and complete patient reported outcome assessments;
and (3) nominated a general practitioner (GP) who agreed to use an
online care management tool. Men were excluded from the study if
they: (1) were too unwell (as determined by their treating specialists);
or (2) had physical, psychological or cognitive difficulties that would
prevent them from participating in the intervention or completing
self‐report outcome measures. The treating specialist (e.g., urologist,
radiation or medical oncologist) introduced the study to the potential
participants when they attended clinic appointments at the site. Men
who expressed interest were referred to an on‐site research nurse
(who operated independently from nurses delivering the intervention)
for further study information and written consent. Upon consenting,
men were asked to nominate a GPwho was subsequently sent written
information about the study. Verbal consent to participate was ob-
tained from the GP via a follow‐up telephone conversation with the
research nurse.
All consented men were asked to nominate one partner/carer,
who was also invited to participate. Partners/carers were required to
be: (1) aged 18 years or older; (2) competent to give informed con-
sent; and (3) able to complete questionnaires. Participation of the
partner/carer was not a requirement for the man to participate in the
study.
2.3 | Intervention
The TrueNTH intervention was a multi‐component integrated model
of care for men with prostate cancer. Components of the program
and care pathway are illustrated in Figure 1. An experienced urology
nurse with demonstrated capabilities in clinical assessment and care
planning, supportive care, advanced communication, teamwork, and
organisational skills was based at each site to coordinate the health
care needs of the participant. This nurse was nominated to be
the local care coordinator responsible to deliver or facilitate the
intervention components for approximately three months via face‐
to‐face consultation, video or telephone support, or email
communication.
After three‐months, men who were on active surveillance or had
completed treatment and no longer required for specialised treat-
ment service (i.e., surgery, radiation) were referred to a Movember
employed central care coordinator who was independent to the
participating sites. The central care coordinator provided ongoing
information and support on an as needed basis and facilitated
referral to relevant clinical or supportive care services to meet
ongoing and newly emergent needs of men using telephone or video
conferencing support as required.
At enrolment, all men received a structured face‐to‐face
consultation with the local care coordinator who comprehensively
assessed their needs related to prostate health, general and psy-
chological health, nutritional status, and supportive care needs. Men
were provided with an evidence‐based education package relevant
to their stage of disease and treatment and decision support material
(e.g., the online P3P Decision Support Program21) if they were newly
diagnosed with prostate cancer and not yet received treatment.
Partners/carers were encouraged to attend the session with the man
F I GUR E 1 Components of the TrueNTH
program and care pathway for men with
prostate cancer
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and were provided with support as appropriate, which included the
provision of relevant information.
The outcome of the initial assessment was communicated to the
man’s treating specialist/team and GP via email or postal mail. This
information was used as the basis for development of a care plan and
referral to appropriate specialist support services according to the
man’s health needs and preferences, preference of treating
specialist/team and the availability of local resources. The local care
coordinator liaised with the man’s GP to facilitate additional as-
sessments for risks or comorbidities. Based on the assessment, the
GP liaised with the treating team to facilitate the management of any
identified risk factors and conditions.
All men were referred to an accredited exercise physiologist and
an accredited practising dietitian either locally or through a cen-
tralised service to receive an evidence‐based exercise prescription
and individualised dietetic services, respectively. They were provided
with information about local peer support programs and were
referred to relevant support services to address their needs relating
to transport, accommodation, finance, legal, employment and respite
services for carers, as required.
The above services were offered to all men regardless their stage
of prostate cancer and treatment received. The needs for specific
prostate cancer related services (as shown in Figure 1) varied bymen’s
stage of disease and treatment received and thereby the specialised
serviceswereby referral at anypointduring the intervention according
to needs. These services were delivered locally where available or
remotely by a central specialist service engaged for thepurposes of this
project. Not all men needed all specialised services.
To ensure the intervention fidelity, a detailed intervention
manual was provided to the care coordinators. All staff involved in
the intervention delivery attended an orientation and skill devel-
opment program, ongoing education and training as required, and
regular team meetings. An online care management tool (cdmNet1)
was used to manage and support care planning, delivery, and review
of the services by the intervention team. Men were provided with
this tool at the initial consultation, which enabled them to access
the individualised care plan and undertake ongoing self‐monitoring
of their symptoms and needs on a 3 monthly basis or when new
symptoms emerged. An alert was sent to the local care coordinator
and GP when assessments were completed. If the man did not want
to use cdmNet to communicate with the care team or access in-
formation, hard copies of information and the care plan were pro-
vided with telephone support.
2.4 | Data collection and measurements
2.4.1 | Recruitment capability and resulting
participant characteristics
The primary outcome for this study was feasibility measured by the
number of eligible patients in the targeted population, number of
consents, reasons for declining participation, and retention rate.
These measures were documented by the research nurse responsible
for recruitment using structured forms.
2.4.2 | Appropriateness and feasibility of delivering
intervention components
Information on intervention delivery and attendancewere captured by
cdmNet. After each initial consultation, the local care coordinators also
completed a log to record the extent to which they delivered inter-
vention activities and the length of the session. Seven sessions were
audio‐recorded with permission from the participants to enable
assessment of the fidelity of the intervention delivery to protocol.
2.4.3 | Suitability of data collection procedures and
proposed outcome measures
Surveys were conducted with participants at enrolment (T0), and at 3
months (T1) and 6 months (T2) after enrolment. A range of validated
questionnaires (Appendix S1) was used to measure patient‐reported
health outcomes, including prostate cancer‐specific quality of life
(EPIC‐26),22 psychological well‐being (GHQ‐12),23,24 experience of
care (PPE‐15),25 supportive care needs (SCNS‐SF34),26 and deci-
sional conflict27/regret.28 The proposed economic outcome mea-
sures, including three health‐related quality of life measures (i.e., EQ‐
5D‐5L,29 AQoL‐8D30 and FACT‐P31), self‐reported health service
usage and cost data were also collected via the survey. The T0 survey
was completed by participants at the clinic on the day of the initial
consultation and follow‐up questionnaires were posted to the par-
ticipants with pre‐paid return envelopes. The research nurse would
aid participants if required. Participants were informed that their
responses were confidential and not supplied to their care providers.
2.5 | Data analysis
All quantitative analyses were performed using SPSS for Windows
(Version 23.0). Descriptive statistics were used to summarise data
relating to the primary feasibility outcomes (i.e., recruitment, reten-
tion, characteristics of participants) and the uptake of the interven-
tion components. The tape recordings of the initial consultation
sessions were reviewed using a checklist that included key inter-
vention components to describe what topics were addressed and to
what extent.
While the study was not powered to assess clinical significance,
one‐way ANOVA was employed to undertake exploratory compar-
isons on the proposed outcome measures over the study period.
Only participants who provided data at all three time
points were included in the test. An alpha level of p ≤ 0.05 was
considered statistically significant. The internal consistency of these
outcome measures was estimated by using Cronbach’s alpha
coefficient with a level of 0.70 considered suitable.
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3 | RESULTS
3.1 | Recruitment capability and participant
characteristics
During the recruitment period between 2015 and 2016 (one site
recruited for 6 months and another site recruited for 12 months), a
total of 183 men with prostate cancer were referred to the study (see
Figure 2). Of the 105 eligible men, 51 consented (consent rate 49%);
of the 31 nominated carers, 13 consented (consent rate 42%).
Baseline demographic characteristics of participants are presented in
Table 1. Most men (n = 47, 92%) were newly diagnosed with localised
prostate cancer at enrolment; among them 70% (n = 33) received
surgery, 13% (n = 6) received radiotherapy, 6% (n = 3) received
multiple treatments, and 11% (n = 5) were undergoing active sur-
veillance during the study. Of the four men with advanced prostate
cancer, three were undergoing hormone treatment and one had
completed surgery at enrolment.
3.2 | Intervention delivery
3.2.1 | Local care coordinator interventions
All men attended the initial consultation with the local care co-
ordinators at enrolment. The themes identified from these sessions
are presented in Table 2. The extent to which various components of
the intervention were addressed in these sessions is reported in
Appendix S2. During the session, information and education com-
ponents of the intervention were explained to the men in great detail.
For approximately one in five men, intervention components relating
to decision support and technology supported monitoring were
addressed a little or not at all. Referrals to sexual counselling,
continence and psychological services were addressed to a lesser
extent than other support services. The average length of the session
was 141 min (SD = 33). The coordinators also spent on average
134 min (SD = 41) organising and/or following‐up the session.
Partners/carers were present at 67% of the sessions (n = 34); and of
these partners/carers, 89% (n = 30) were involved completely or to a
great extent in the sessions. Excluding the initial consultation, local
care coordinators made a total of 350 episodes of contact/consul-
tation with the men to provide ongoing monitoring and support; and
the average length of each contact/consultation was 16 min
(SD = 16).
3.2.2 | Number and delivery mode of intervention
components
A total of 838 episodes of contact/consultation were made with the
intervention team, including 401 contacts made by the local care
coordinators, 80 by the central care coordinators, 180 by dietitians,
122 by exercise physiologists, 53 by psychiatrists, one by a sexual
health specialist and one by a continence consultant. Each man
F I GUR E 2 Flow diagram of the study
procedure
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TAB L E 1 Characteristics of participants at baseline (51 men and 13 partners/carers)
Characteristics Men Partners/Carers
Age (years) Mean 62.9 (SD = 6.9, range 49–76) Mean 58.5 (SD = 7.6, range 46–69)
n (%) n (%)
Age groups (years) 40–49 1 (2) 2 (15)
50–59 15 (29) 3 (23)
60–69 28 (55) 8 (62)
70–79 7 (14) 00 (0)
Area of residence Major cities 11 (22) 00 (0)
Inner regional 39 (77) 12 (92)
Outer regional 1 (2) 1 (8)
Remote 00 (0) 00 (0)
Very remote 00 (0) 00 (0)
Marital status Married/de facto 38 (75) 12 (100)
Widowed 1 (2) 00 (0)
Divorced/separated 9 (18) 00 (0)
Never married 3 (6) 00 (0)
Education level No formal schooling/Primary school 2 (4) 00 (0)
Secondary school 21 (41) 4 (31)
Trade apprenticeship 8 (16) 00 (0)
TAFE college 11 (22) 3 (23)
University degree or higher 9 (18) 4 (31)
Other 00 (0) 2 (15)
Employment status Working full/part‐time 21 (41) 7 (54)
Retired 22 (43) 5 (38)
Home duties 00 (0) 1 (8)
Unemployed 7 (14) 00 (0)
Sick/on leave/disability 1 (2) 00 (0)
Annual gross income (individual) < $20,000 16 (31) 5 (42)
$20,000‐$39,999 11 (22) 1 (8)
$40,000‐$59,999 10 (20) 1 (8)
$60,000‐&79,999 7 (14) 3 (25)
≥ $80,000 2 (4) 00 (0)
No information provided 5 (10) 2 (17)
Being a carer to dependents Dependent child 10 (20) 1 (8)
Aged spouse/relative/friend 1 (2) 2 (17)
Person with a disability 2 (4) 00 (0)
No dependents 37 (72) 9 (75)
Other 1 (2) 00 (0)
Health concession card holdera 29 (58) 6 (46)
(Continues)
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received a median of 16 contacts. Approximately 9% of the contacts
were conducted in person, 76% were made via phone, and 15% via
email or online teleconference or other modes.
3.2.3 | Completion rates
Nearly all men (98%) and all carers completed the full 6‐months
intervention, with only one man withdrawing after two months
due to personal and family issues. No adverse health events were
experienced or reported by participants as a result of the
intervention.
3.2.4 | Use of technology
Data captured by cdmNet showed that it was used for supporting the
delivery of the intervention in a variety of ways. The local care co-
ordinators used it to assess key patient‐reported outcomes (i.e.,
prostate cancer specific symptoms, distress level and initial nutrition
T A B L E 1 (Continued)
Characteristics Men Partners/Carers
Eligible for IPTAA)b 15 (33) Not applicable
Willingness to provide consent for collection of medicare datac 49 (96) 13 (100)
Abbreviations: IPTAAS, isolated patients travel & accommodation assistance scheme; SD, standard deviation.
aFor people on a low income or who have reached qualifying age for Age Pension to access to Pharmaceutical Benefits Scheme prescription items, and
certain Medicare services, at a cheaper rate.
bIPTAAS is a subsidy program which provides financial assistance to help with travel and accommodation costs for people who need to travel long
distances to access specialist medical services not available locally.
cMedicare data are health related statistics administered by the Australian government which provide information on general practitioner, specialist,
diagnostic test and prescription pharmaceutical use.
TAB L E 2 Topics addressed by local care coordinators in initial consultations
Themes Examples
Screening and assessment � Assessment of prostate cancer specific symptoms, distress and nutrition screening using
the tools as per protocol.
� Assessment of prostate cancer stage, treatments received or treatment intention,
medication, and comorbidities.
Navigation and referral � Informing men about the TrueNTH program and central care coordination, e.g., what
support and services would be available, who would contact the man and how the
services would be delivered; role of the general practitioner (GP); communication be-
tween care coordinators, treating specialists and other care providers.
� Introduction of care plan and multidisciplinary approach.
Information provision and education � Introduction of reliable online information resources and provision of TrueNTH edu-
cation package, e.g., (PCFA), Andrology Australia, cancer Council online fact sheets and
booklets.
� Explanation about stage of disease, treatment options, prognosis, and test results etc.
� Discussion of post treatment issues, such as side effects of treatment on sexual function
and penile rehabilitation, continence; activities that enhance the recovery.
Decision support � Introduction of the personal patient profile (P3P).
Self‐management support � Providing access to and demonstrating the use of cdmNet.
Practical and peer support � Introduction of local prostate cancer support groups.
� Discussion of financial issues related to cancer treatment.
� Discussion of carer and family support.
Advanced prostate cancer comorbidities management � Explanation about the role of GP.
� Introduction of the exercise and nutrition components of the TrueNTH program.
Note: Based on the recordings of seven initial consultation sessions.
Abbreviation: PCFA, prostate cancer Foundation of Australia.
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screening), identify individual needs, and refer men to relevant ser-
vices. The intervention team used it for communication and to
manage and support care planning, care delivery and review. There
was no record that the tool was used by referring specialists or by
GPs. Men’s progress was updated with their specialists and GPs via
telephone conversations, emails or letters prepared by care
coordinators.
3.3 | Data collection procedures and outcome
measures
All participants completed T0 survey, 35 men and 12 partners/carers
returned T1, and 36 men and all partners/carers returned T2 survey.
Participants appeared to have no difficulty completing the health‐
related outcome measures independently as there was little
missing data (<3%). The internal consistency reliability of these
measures (as shown in Appendix S3) was satisfactory (Cronbach’s
α = 0.67‐0.96), except for the urinary obstructive subscale (Cron-
bach’s α = 0.51) of the EPIC questionnaire.
Some participants needed assistance from the research assistant
to complete the health service usage questionnaire as they had dif-
ficulty spelling drug names, recalling all of the services and medicines
used, and the relevant costs over the preceding three months. As a
result, 2% of men and 5% of partner/carer responses were missing on
the health services usage questions. However, men often provided
more data regarding their use of pharmaceuticals than was reques-
ted. In addition, 96% men and all partners/carers indicated a will-
ingness to consent to the researchers accessing their Medicare data
for health services usage data. The three health‐related quality of life
measures (i.e. EQ‐5D‐5L, AQoL‐8D and FACT‐P) showed high
completion rates (missing data <2%).
Scores from key patient‐reported health outcome measures
collected at each time point are summarised in Appendix S3. Symp-
tom severity was highest for sexual dysfunction at all time points.
Men reported a significant improvement regarding urinary obstruc-
tion(p = 0.03), but worse sexual health (p < 0.001) and urinary in-
continence (p < 0.01) over time. Levels of psychological distress in
men did not change (p = 0.73) over time with 57% (n = 29) at T0, 54%
(n = 19) at T1 and 63% (n = 22) at T2 reporting that they did not have
any psychological distress. Around 18% of the men (n = 6) at T1 and
27% (n = 9) at T2 reported that they did not experience any problems
with their care. However, this change was not statistically significant
(p = 0.30). There were no statistically significant changes over time in
terms of supportive care needs (p = 0.06‐0.64) and decision regret
(p = 0.39) for men.
4 | DISCUSSION
This study assessed the feasibility of implementing an integrated,
multicomponent care model designed to address critical areas of care
for men and their partners/carers affected by prostate cancer in
Australia. Our findings are that the program was accepted by men,
was largely implemented as per protocol with high completion rates
and no adverse events. The proposed evaluation procedures were
appropriate. However, some important issues were raised in this
study that have implications for future studies involving multicom-
ponent interventions.
Interest in the program by the treating team was high and use
of existing clinical networks as referral sources was effective. Over
180 referrals were received from the two regional settings during
the recruitment period. Of note, around 40% of the referrals did
not meet the inclusion criteria relating to time since diagnosis. The
strict inclusion criteria in the present study were chosen to enhance
homogeneity of the sample and enable testing of the full inter-
vention pathway from the beginning of their cancer journey. The
high number of ineligible referrals due to duration of diagnosis
highlights the clinician’s and/or the man’s desire to access sup-
portive care.
The main reason that eligible men declined participation in this
study was ‘lack of interest’ or ‘not being in need of supportive care’
(50%), ‘feeling overwhelmed/perceived burden’ (20%) and ‘no desire
to use computers or smart devices’ (17%). Such concerns highlight
the need for active strategies to enhance men’s participation in the
program, such as providing additional written information to explain
the purpose and procedures of the program, as well as possible
benefits and risks; offering hands‐on support for using computers/
smart devices; and offering alternative modes of service and
communication. Post Covid‐19 pandemic it is likely that the ‘no
desire to use computers or smart devices’ sentiment will be much
reduced since all age groups of Australians have embraced computer‐
based forms of communication in much greater numbers than
previously.
The recruitment resulted in a sample of men who were of a
similar age range to men affected by prostate cancer in Australia.1
Most men were from a regional area and one third of them had to
travel long distances (eligible for government subsidy) for treatment
and specialist appointments. Around 40% took time off work to
participate in the face‐to‐face services. Therefore, interventions that
are delivered remotely via telephone or digital health were appro-
priate and acceptable for the current sample. We suggest that while
some men were reluctant to participate in the study due to concerns
about use of technology, most intervention activities (91%) were
carried out remotely via telephone or digital health.
In terms of the data collection procedures and outcome mea-
sures, participants had no difficulty independently completing
questions related to their health and responded with minimal
missing data. The internal consistency of the key patient‐reported
health outcome measures with our sample was similar to that re-
ported in the previous studies. The four quality of life measures that
were tested in the study showed equally high acceptability and
response rates over time. Two of them (AQoL‐8D, FACT‐P) contain
35 and 40 items respectively, one contains 26 items (EPIC‐26), and
one (EQ‐5D‐5L) contains 5 items. The measures with most concise
items would be more acceptable for the larger trial. The advantage
YATES ET AL. - 1551
of the EQ‐5D‐5L and the AQoL‐8D is that generic health utility
scores can be generated for comparative economic evaluation
purposes (i.e., both instruments are multi‐attribute utility in-
struments (MAUIs) usable in a variety of settings).32 The AQoL‐8D
has more sensitivity to change than the EQ‐5D‐5L but is consid-
erably longer. Both have been extensively used in trials to describe
the self‐rated health, but the EQ‐5D‐5L has had greater application
in prostate cancer patients.33 As a result, the EQ‐5D‐5L would be
recommended for a larger study as the preferred economic instru-
ment. The two measures (FACT‐P and EPIC‐26) were tested as
patient relevant outcome measures and as the comparison cancer
specific quality of life measure for the generic economic in-
struments. On balance the two shorter quality of life measures
would be chosen for a larger study–the EPIC‐26 (disease specific)
and the EQ‐5D‐5L (generic).
4.1 | Clinical implications
Overall, the uptake of intervention components was high, and the
intervention was implemented as proposed. This included uptake of
the referral to remotely provided nutrition and exercise management
services, and other support following treatment completion. Smaller
numbers of referrals were made to specialised services including
sexual counselling, continence, and psychological services. These
lower referral rates could reflect that such referrals were seen to be
necessary only for severe cases or reflect reluctance on the part of
local care coordinators to share care with others. It might also reflect
reluctance on the part of patients to accept help for these concerns.
A previous study34 of a nurse‐led prostate cancer survivorship ser-
vice in UK reported that 22% of men who initially declined to attend
a supportive care program asked for a supportive care clinic
appointment after attending education sessions. Our finding high-
lights the need to develop clear protocols to facilitate needs‐based
referrals, and to actively work with patients to manage concerns
about referrals to these services.
Partners/carers of the men were also actively involved in the
program. Although only a quarter of partners/carers (13 out of 51)
participated in the study, two thirds of the initial consultation ses-
sions (34 out of 51) included partners/carers and these sessions were
well accepted.
We suggest that the online care management tool supported the
implementation of the intervention in multiple ways, including facil-
itating the team communication. Even though the participating GPs
agreed to use the tool, none of them actually accessed it during the
study, nor did the treating specialists. For this reason, the men’s
medical team received progress updates via telephone and letters
written by care coordinators. It was also challenging to monitor and
obtain data on the services provided by the local service providers
outside of the public health system. The barriers to using the tool for
these health professionals need to be explored as effective commu-
nication within the patients’ care team and care coordination across
service providers and settings are key to the successful management
of patient care.
4.2 | Study limitations
This study was designed to assess the feasibility and acceptability,
but not the effectiveness of the intervention. Nonetheless, some
preliminary observations can be made regarding the validity and
sensitivity of the tools. The changes regarding prostate cancer spe-
cific quality of life, while not designed to be evaluated for statistical
significance, were in line with other patient‐reported outcome
studies,4,5 in which urinary obstructive symptoms improved with
treatment over the time. Urinary continence and sexual functioning
declined initially and improved with time after treatment. Other
limitations of the study include the use of convenience study sites
and that most patients were newly diagnosed and were undertaking
or had just finished their treatment. While not all men needed all
services provided by the intervention during the study period,
participation in the study likely increased men’s knowledge of disease
and treatment effects and promoted awareness of such support
which could benefit these men in the long‐term. Moreover, while
referral to specialist services for side‐effects of treatment such as
urinary and sexual function was not high, the use of experienced
nurses with expertise in these areas likely has important benefits as
some men would prefer that such sensitive topics are addressed by
known health professionals.
5 | CONCLUSIONS
In this study we have demonstrated the feasibility of implementing
an integrated multicomponent care model for men affected by
prostate cancer. Future studies need to focus on how to engage with
men and their partners/carers to ensure similar interventions take
into account their concerns and to reduce burden. Consideration of
health literacy and tailoring of the intervention to personal circum-
stances are integral to success of long‐term interventions such as
TrueNTH. Additional strategies to encourage the involvement of GPs,
if they are to take on a more active role in follow up care, are needed.
Clear protocols that guide when referrals should be made to
specialist support services will be required to ensure appropriate use
of these services.
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